☆ 4.6 Article

In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys

Brian Lauritzen et al.

Summary: In nonclinical studies, Mim8 demonstrated good tolerability in cynomolgus monkeys and subcutaneous administration at clinically relevant exposure levels resulted in relevant pharmacodynamic effects without signs of thrombi or excessive coagulation activation.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Letter Hematology

Thrombin generation assay modifications needed for its application to monitoring of replacement therapy for haemophilia

Leonid A. Parunov et al.

HAEMOPHILIA (2021)

Add to Collection

Article Hematology

A serine loop in tissue factor mediates substrate selectivity by the tissue factor-factor VIIa complex

Fabienne Birkle et al.

Summary: The study reveals that the TF-FVIIa complex actively selects between its major protein substrates, FIX and FX, mediated by a TF serine loop. Alterations in the serine loop length significantly affect the activation rates of FIX and FX differently, indicating a role in substrate selectivity. These findings provide new insights into the mechanisms of thrombotic diseases.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Hematology

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

Christophe Schmitt et al.

Summary: Emicizumab functions to restore effective hemostasis in individuals with hemophilia A by bridging activated factor IX and FX. Pharmacokinetic and pharmacodynamic assessments in patients with FVIII inhibitors showed that Emicizumab maintained therapeutic plasma levels and correlated with FVIII-like activity and thrombin generation, potentially converting severe hemophilia A to a milder phenotype.

THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Hematology

Comparison of bypassing agents in patients on emicizumab using global hemostasis assays

Hande Kizilocak et al.

Summary: The study found that adding BPA to plasma from patients on emicizumab increased thrombin generation, and licensed doses of aPCC led to excessive thrombin generation. Thromboelastography was not sensitive enough. Clinical studies are needed to confirm the safety of using lower doses of aPCC with emicizumab.

HAEMOPHILIA (2021)

Add to Collection

Article Hematology

Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies

Marisa Ninivaggi et al.

Summary: Thrombin generation (TG) assay is a comprehensive tool for assessing hemostatic system functionality, but lack of standardization in its execution leads to poor correlation between test results. Recommendations based on survey and literature review address interlaboratory variation, aiming to harmonize methods and laboratories for supporting patient diagnosis and management with TG.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Hematology

A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Henrik Ostergaard et al.

Summary: Mim8 is a bispecific antibody that shows efficient hemostatic effects for treating hemophilia A by mimicking activated FVIII, with high potency and efficacy based on preclinical data.

BLOOD (2021)

Add to Collection

Review Hematology

Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine

Francois Depasse et al.

Summary: Thrombin generation assay, also known as thrombin generation test, is a global assay that provides a comprehensive view of hemostasis balance by continuously and simultaneously measuring thrombin formation and inhibition. Standardization and automation of this assay have provided researchers, clinical laboratories, and the pharmaceutical industry with a versatile tool for various clinical and non-clinical applications.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Hematology

A hemophilia A mouse model for the in vivo assessment of emicizumab function

Stephen Ferriere et al.

BLOOD (2020)

Add to Collection

Article Hematology

A bispecific antibody demonstrates limited measurability in routine coagulation assays

Rudolf Hartmann et al.

BLOOD COAGULATION & FIBRINOLYSIS (2020)

Add to Collection

Article Hematology

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A

Georg Gelbenegger et al.

THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Hematology

Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence

Nina C. Leksa et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)

Add to Collection

Article Hematology

Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program

Gallia G. Levy et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)

Add to Collection

Article Hematology

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A

H. Marijke van den Berg et al.

BLOOD (2019)

Add to Collection

Article Biotechnology & Applied Microbiology

Emicizumab for the prevention of bleeds in hemophilia A

Johnny Mahlangu

EXPERT OPINION ON BIOLOGICAL THERAPY (2019)

Add to Collection

Review Pharmacology & Pharmacy

Emicizumab: A Review in Haemophilia A

Hannah A. Blair

DRUGS (2019)

Add to Collection

Article Hematology

In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents

R. Hartmann et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)

Add to Collection

Review Hematology

Practical aspects of extended half-life products for the treatment of haemophilia

Thierry Lambert et al.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Johannes Oldenburg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A

F. Peyvandi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Hematology

Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness

K. Yada et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)

Add to Collection

Article Hematology

Coagulation procofactor activation by factor XIa

M. F. Whelihan et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)

Add to Collection

Article Biochemistry & Molecular Biology

Characterization of novel forms of coagulation factor XIa - Independence of factor XIa subunits in factor IX activation

Stephen B. Smith et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2008)

Add to Collection

Review Hematology

Activation of factor VIII and mechanisms of cofactor action

PJ Fay

BLOOD REVIEWS (2004)

Add to Collection

Article Hematology

Calibrated automated thrombin generation measurement in clotting plasma

HC Hemker et al.

PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.